{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"}]}],"title":"Any infection or infestation post-infusion"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"}]}],"title":"Any infection or infestation of Grade 3 or higher post-infusion"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"1"}],"units":"Participants"}],"description":"Incidence and severity of opportunistic infections following AUTO4 infusion.","groups":[{"description":"Patients received 25x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG000","title":"Phase I Dose Escalation - Cohort 1"},{"description":"Patients received 75x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG001","title":"Phase I Dose Escalation - Cohort 2"},{"description":"Patients received 225x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG002","title":"Phase I Dose Escalation - Cohort 3"},{"description":"Patients received 450x10\\^6 CAR T-positive cells","id":"OG003","title":"Phase I Dose Escalation - Cohort 4"},{"description":"Patients received 225x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG004","title":"Phase I Dose Escalation With Modified Manufacturing Process - Cohort 3"},{"description":"Patients received 450x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG005","title":"Phase I Dose Escalation With Modified Manufacturing Process - Cohort 4"},{"description":"Patients received 900x10\\^6 RQR8/aTRBC1 CAR T-positive cells","id":"OG006","title":"Phase I Dose Escalation With Modified Manufacturing Process - Cohort 5"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"24 months post treatment","title":"To Assess the Overall Safety and Tolerability of AUTO4.","type":"SECONDARY","unitOfMeasure":"Participants"}